🚀 VC round data is live in beta, check it out!
Santhera Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Santhera Pharma and similar public comparables like LENZ Therapeutics, Organogenesis, Vicore Pharma Holding, Northwest Biotherapeutics and more.
Santhera Pharma Overview
About Santhera Pharma
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives the majority of its revenue from the European Union.
Founded
2004
HQ
Employees
85
Website
Sectors
Financials (LTM)
EV
$349M
Santhera Pharma Financials
Santhera Pharma reported last 12-month revenue of $107M and EBITDA of $4M.
In the same LTM period, Santhera Pharma generated $60M in gross profit, $4M in EBITDA, and had net loss of ($23M).
Revenue (LTM)
Santhera Pharma P&L
In the most recent fiscal year, Santhera Pharma reported revenue of $50M and EBITDA of ($33M).
Santhera Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $107M | XXX | $50M | XXX | XXX | XXX |
| Gross Profit | $60M | XXX | $30M | XXX | XXX | XXX |
| Gross Margin | 56% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $4M | XXX | ($33M) | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | (67%) | XXX | XXX | XXX |
| EBIT Margin | (13%) | XXX | (80%) | XXX | XXX | XXX |
| Net Profit | ($23M) | XXX | ($51M) | XXX | XXX | XXX |
| Net Margin | (22%) | XXX | (102%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Santhera Pharma Stock Performance
Santhera Pharma has current market cap of $320M, and enterprise value of $349M.
Market Cap Evolution
Santhera Pharma's stock price is $22.50.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $349M | $320M | 1.7% | XXX | XXX | XXX | $-3.58 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSanthera Pharma Valuation Multiples
Santhera Pharma trades at 3.3x EV/Revenue multiple, and 98.3x EV/EBITDA.
EV / Revenue (LTM)
Santhera Pharma Financial Valuation Multiples
As of April 18, 2026, Santhera Pharma has market cap of $320M and EV of $349M.
Equity research analysts estimate Santhera Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Santhera Pharma has a P/E ratio of (13.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $320M | XXX | $320M | XXX | XXX | XXX |
| EV (current) | $349M | XXX | $349M | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBITDA | 98.3x | XXX | (10.5x) | XXX | XXX | XXX |
| EV/EBIT | (25.3x) | XXX | (8.7x) | XXX | XXX | XXX |
| EV/Gross Profit | 5.8x | XXX | 11.6x | XXX | XXX | XXX |
| P/E | (13.6x) | XXX | (6.3x) | XXX | XXX | XXX |
| EV/FCF | (8.6x) | XXX | (8.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Santhera Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Santhera Pharma Margins & Growth Rates
Santhera Pharma's revenue in the last 12 month grew by 38%.
Santhera Pharma's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.9M for the same period.
Santhera Pharma's rule of 40 is 103% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Santhera Pharma's rule of X is 191% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Santhera Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 38% | XXX | 82% | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | (67%) | XXX | XXX | XXX |
| EBITDA Growth | 1409% | XXX | (35%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 103% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 191% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 21% | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 23% | XXX | 50% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 25% | XXX | 68% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 145% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Santhera Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Santhera Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| LENZ Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Organogenesis | XXX | XXX | XXX | XXX | XXX | XXX |
| Vicore Pharma Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Northwest Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Hansa Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Santhera Pharma M&A Activity
Santhera Pharma acquired XXX companies to date.
Last acquisition by Santhera Pharma was on XXXXXXXX, XXXXX. Santhera Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Santhera Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSanthera Pharma Investment Activity
Santhera Pharma invested in XXX companies to date.
Santhera Pharma made its latest investment on XXXXXXXX, XXXXX. Santhera Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Santhera Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Santhera Pharma
| When was Santhera Pharma founded? | Santhera Pharma was founded in 2004. |
| Where is Santhera Pharma headquartered? | Santhera Pharma is headquartered in Switzerland. |
| How many employees does Santhera Pharma have? | As of today, Santhera Pharma has over 85 employees. |
| Is Santhera Pharma publicly listed? | Yes, Santhera Pharma is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Santhera Pharma? | Santhera Pharma trades under SANN ticker. |
| When did Santhera Pharma go public? | Santhera Pharma went public in 2006. |
| Who are competitors of Santhera Pharma? | Santhera Pharma main competitors are LENZ Therapeutics, Organogenesis, Vicore Pharma Holding, Northwest Biotherapeutics. |
| What is the current market cap of Santhera Pharma? | Santhera Pharma's current market cap is $320M. |
| What is the current revenue of Santhera Pharma? | Santhera Pharma's last 12 months revenue is $107M. |
| What is the current revenue growth of Santhera Pharma? | Santhera Pharma revenue growth (NTM/LTM) is 38%. |
| What is the current EV/Revenue multiple of Santhera Pharma? | Current revenue multiple of Santhera Pharma is 3.3x. |
| Is Santhera Pharma profitable? | Yes, Santhera Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Santhera Pharma? | Santhera Pharma's last 12 months EBITDA is $4M. |
| What is Santhera Pharma's EBITDA margin? | Santhera Pharma's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of Santhera Pharma? | Current EBITDA multiple of Santhera Pharma is 98.3x. |
| What is the current FCF of Santhera Pharma? | Santhera Pharma's last 12 months FCF is ($40M). |
| What is Santhera Pharma's FCF margin? | Santhera Pharma's last 12 months FCF margin is (38%). |
| What is the current EV/FCF multiple of Santhera Pharma? | Current FCF multiple of Santhera Pharma is (8.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.